IFNB1 and myeloid sarcoma: Finding increased T cells reactive to both latent and lytic EBV antigens supports the hypothesis that latent-lytic EBV cycling is boosting T-cell memory and diversity in people with MS and strengthens the case for testing EBV antiviral agents in MS.110 In this study, people with MS treated with natalizumab had amplified T-cell responses to EBV; i.e. they had an even broader EBV reactive T-cell repertoire.110 Interferon-beta, a putative antiviral and anti-CD20 treatment targeting latent EBV in B cells, did not appear to modulate EBV-specific T cells.110